Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.51 |
| ▸ | FAAH | O00519 | 2/20 | 0.47 |
| ▸ | CNR1 | P21554 | 5/20 | 0.46 |
| ▸ | PPARA | Q07869 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 3/20 | 0.44 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21300635 | 1.00 | TRPV1 (0.51) | TRPV1FAAHCNR1PPARACNR2 | |
| SCHEMBL16024012 | 1.00 | TRPV1 (0.51) | TRPV1FAAHCNR1PPARACNR2 | |
| SCHEMBL16154859 | 0.89 | TRPV1 (0.50) | TRPV1FAAHCNR1PPARAPLA2G2A | |
| SCHEMBL17685762 | 0.89 | TRPV1 (0.50) | TRPV1FAAHCNR1PPARAPLA2G2A | |
| SCHEMBL16013719 | 0.85 | MGLL (0.48) | CNR1CNR2 | |
| SCHEMBL16013720 | 0.85 | MGLL (0.48) | CNR1CNR2 | |
| SCHEMBL16013182 | 0.84 | CNR1 (0.49) | CNR1PPARACNR2 | |
| SCHEMBL16013183 | 0.84 | CNR1 (0.49) | CNR1PPARACNR2 | |
| SCHEMBL16012357 | 0.83 | THRB (0.44) | CNR1PPARACNR2 | |
| SCHEMBL31442491 | 0.83 | CNR1 (0.51) | CNR1PPARACNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3608308-B1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | NOVARTIS AG (CH) | 2021-07-21 | — | — | EP | disclosed |
| US-10792361-B2 | Lipids and lipid compositions for the delivery of active agents | NOVARTIS AG (CH) | 2020-10-06 | — | — | US | disclosed |
| EP-3608308-A1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | Novartis AG (CH) | 2020-02-12 | — | — | EP | disclosed |
| EP-2964608-B1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | NOVARTIS AG (CH) | 2019-08-28 | — | — | EP | disclosed |
| US-20180369386-A1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2018-12-27 | — | — | US | disclosed |
| US-10124065-B2 | Lipids and lipid compositions for the delivery of active agents | NOVARTIS AG (CH) | 2018-11-13 | — | — | US | disclosed |
| US-20160106842-A1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2016-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10124065-B2 | Lipids and lipid compositions for the delivery of active agents | LIPA, LPAR1, LPAR4 | TRPV1 2102/4885FAAH 1529/4885CNR1 1158/4885 |
| US-20180369386-A1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | LIPA, LPAR1, LPAR4 | TRPV1 2102/4885FAAH 1529/4885CNR1 1158/4885 |
| US-20160106842-A1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | LIPA, LPAR1, LPAR4 | TRPV1 2102/4885FAAH 1529/4885CNR1 1158/4885 |
| US-10792361-B2 | Lipids and lipid compositions for the delivery of active agents | LIPA, LPAR1, LPAR4 | TRPV1 2102/4885FAAH 1529/4885CNR1 1158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.